Showing results (481-490 of 635) with videos related to

Sort By:
Pageof 64
BMJ Open|March 27, 2025
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II studyRomina M Roesch, Johannes Schnorbach, Laura V Klotz, et al.
Gut|September 30, 2024
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinomaHenrike Salié, Lara Wischer, Antonio D'Alessio, et al.
International Journal of Cancer|September 19, 2020
Integrating proteomics into precision oncologyLeonie W Wahjudi, Stephan Bernhardt, Khalid Abnaof, et al.
Plos One|August 27, 2019
Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADSJan Philipp Radtke, Francesco Giganti, Manuel Wiesenfarth, et al.
NPJ Precision Oncology|May 23, 2024
Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathologyMarco Gustav, Nic Gabriel Reitsam, Zunamys I Carrero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2017
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment ResponseAlexander Muckenhuber, Anne Katrin Berger, Anna Melissa Schlitter, et al.
BMC Cancer|October 4, 2022
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapyJonas Leichsenring, Valentina Vladimirova, Christine Solbach, et al.
Molecular Cancer|July 22, 2025
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trialAnton Lahusen, Manfred P Lutz, Rui Fang, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 24, 2020
E-cadherin to P-cadherin switching in lobular breast cancer with tubular elementsMatthias Christgen, Stephan Bartels, Jana L van Luttikhuizen, et al.
Pageof 64